公开(公告)号：US20160289210A1

公开(公告)日：2016-10-06

申请号：US15033770

申请日：2014-11-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guanglin Luo ,  Ling Chen ,  Gene M. Dubowchik ,  Swanee E. Jacutin-Porte ,  Prasanna Sivaprakasam ,  John E. Macor

IPC: C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D513/04 ,  C07D487/08 ,  C07D417/12 ,  C07D417/14 ,  C07D409/14 ,  C07D413/14

CPC classification number: C07D401/12 ,  C07D213/81 ,  C07D401/04 ,  C07D401/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D487/08 ,  C07D513/04

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

Abstract translation: 本公开内容通常涉及式I化合物，包括其盐，以及使用该化合物的组合物和方法。 这些化合物是NR2B受体的配体，拮抗剂，可用于治疗中枢神经系统的各种疾病。

公开(公告)号：US20160272621A1

公开(公告)日：2016-09-22

申请号：US15033813

申请日：2014-11-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Guanglin Luo ,  Ling Chen ,  Gene M. Dubowchik ,  Swanee E. Jacutin-Porte ,  Vivekananda M. Vrudhula ,  Senliang Pan ,  Prasanna Sivaprakasam ,  John E. Macor

IPC: C07D401/14 ,  C07D487/04 ,  C07D471/04 ,  C07D413/14 ,  C07D405/14

CPC classification number: C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.

公开(公告)号：US09409922B2

公开(公告)日：2016-08-09

申请号：US14619213

申请日：2015-02-11

Applicant: Bristol-Myers Squibb Company

Inventor： Kevin Peese ,  Zhongyu Wang ,  John F. Kadow ,  Prasanna Sivaprakasam ,  B. Narasimhulu Naidu

IPC: C07D471/04 ,  C07D498/22

CPC classification number: C07D498/22 ,  C07D471/04

Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

Abstract translation: 本公开一般涉及式I化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。 本公开提供了HIV的新型抑制剂，含有这些化合物的药物组合物，以及使用这些化合物治疗HIV感染的方法。